Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,662 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type I Clear all
Completed Phase 1 Interventional

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

NCT00606112
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2009 · Synced Oct 14, 2026, 8:55 PM EDT
Recruiting No phase listed Observational

Type 1 Diabetes Extension Study

NCT02734277
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
12
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Recruiting Not applicable Interventional

InvesT1D: Promoting Adolescent Investment in Diabetes Care

NCT06384911
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Financial Incentives Program
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 14, 2026, 8:55 PM EDT
Completed No phase listed Observational

Management of Type 1 Diabetes Among Adolescents

NCT00340639
View directory record Official record
Conditions
Type I Diabetes
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents

NCT00097071
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 18 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 14, 2026, 8:55 PM EDT
Not yet recruiting Early Phase 1 Interventional

Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes

NCT07395050
View directory record Official record
Conditions
Stage 3 Type 1 Diabetes
Interventions
AutoCD6-CAR Treg cells
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Recruiting Not applicable Interventional

Circadian Mechanisms, Glucose, and CV Risks in T1D

NCT06624046
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Sleep stability intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

NCT00913497
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
insulin glulisine, insulin aspart
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
4 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435
View directory record Official record
Conditions
Hypoglycemia
Interventions
Insulin, Glucose, Potassium phosphate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in Type 1 Diabetes

NCT01722240
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide 1.8mg, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Hybrid Closed Loop in High Risk Youth With Type 1 Diabetes

NCT04807374
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control IQ
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 14, 2026, 8:55 PM EDT
Recruiting Not applicable Interventional

APP-MNT: App-Enhanced Medical Nutrition Therapy on Glycemic Outcomes and Quality of Life

NCT07773779
View directory record Official record
Conditions
Diabetes (Insulin-requiring, Type 1 or Type 2)
Interventions
Undermyfork Care App, Usual Care
Device · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D

NCT02343146
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Type One Training (TOT)
Behavioral
Lead sponsor
Randi Streisand
Other
Eligibility
21 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 14, 2026, 8:55 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

T1DTechCHW: Enhancing the Community Health Worker Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups

NCT05211869
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes, Young Adult, Diabetes Mellitus
Interventions
T1D-CATCH
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Adult Accuracy Study of the Enlite 3 Glucose Sensor

NCT02246582
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Enlite 3, Guardian Mobile App, 640G Insulin Pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
14 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Escondido, California • Walnut Creek, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 8:55 PM EDT
Not yet recruiting Not applicable Interventional

Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction

NCT07165327
View directory record Official record
Conditions
Gestatiaonl Diabetes Mellitus, Pregnancy, Diabetes in Pregnancy, Insulin Dependent Diabetes Mellitus, Insulin
Interventions
Injection Port for Insulin Administration, Single-Use Insulin Needles
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 14, 2026, 8:55 PM EDT
Terminated Phase 3 Interventional

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

NCT01308437
View directory record Official record
Conditions
Type I Diabetes
Interventions
Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 14, 2026, 8:55 PM EDT
Completed No phase listed Observational

Psychosocial Functioning in Young Adults With Type 1 Diabetes

NCT02874612
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Psychosocial Survey Questionnaires
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 24 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT02715193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetes
Interventions
REMD-477, Placebo Comparator
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Breakfast Nutrition and Inpatient Glycemia

NCT01805414
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2, Cardiovascular Disease, Hyperglycemia
Interventions
Modified Carbohydrate Breakfast, Control Breakfast
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Overnight Closed Loop Study in U.S.

NCT01857973
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Hybrid Closed Loop
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Escondido, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 14, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Oct 14, 2026, 8:55 PM EDT